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  Targeted cancer therapy (TCT) is distinct from other medical 
modalities, such as traditional chemotherapy, surgery, and external 
radiation therapy, as it targets cancer cells expressing specific 
biomarkers. Recently, there have been several approaches for TCT 
such as targeted chemotherapy, radionuclide therapy, and photodynamic 
II
therapy which are preferring to minimize normal cell damage against 
tumor cells. As an ideal agent for TCT, small molecule, peptide or 
protein has to contain high binding property to tumor-specific 
biomarker, low non-selective distribution in normal organs, and  long 
uptake in tumor cells including cell-internalization. In this study, we 
designed an in vivo intermolecular click reaction, which is named as 
'Duet Bioorthogonal Clasp (DBC)', between different peptides that had 
situated in same tumor-specific receptors, after the respective injecting 
in tumor animal model. This strategy means that the strong and tight 
receptor cluster via in vivo click reaction induces endocytosis of the 
mixture of receptors and peptides into tumor cells and then results 
significant improvement of the tumor uptake of peptide as well as 
therapeutic effect. Therefore, integrin αvβ3 receptor and cyclic RGD 
analog peptide are selected as a tumor-specific biomarker related with 
angiogenesis and a molecule with high binding affinity to integrins, 
respectively.  In addition, the RGD analog peptide was prepared to 
measure its biodistribution as well as single photon emission computed 
tomography (SPECT) imaging study through the corresponding of a 
radioisotope (123I or 125I).
  The result showed that the two different RGD peptides bound to 
the integrin αvβ3 receptors were significantly moved to into tumor 
cells, by using Fluorescence Resonance Energy Transfer (FRET) 
microscopy. In the SPECT imaging experiment using the 
radioiodine-labeled RGD peptide, DBC maintained 81% of tumor 
uptake 2 h post-injection compared to its initial uptake (vs. control 
tumor uptake was remained 39% at the same time point). After 24 h 
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postinjection, 60% of tumor uptake still observed.
  In conclusion, DBC is demonstrated that it can generate the strong 
cluster between integrin receptors near cancer cells which induce 
cancer cell internalization. These results suggest that this methode can 
pave the way to various successful application of a therapeutic 
molecules or radioisotope capable of cell-internalization  for TCTs. 
Keywords : targeted cancer therapy, internalization, angiogenesis, RGD 
peptides, cluster
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INTRODUCTION
1. Targeted cancer therapies (TCTs)
  Cancer remains the leading cause of death worldwide for decades, 
treatment modalities for cancer has included surgery, external radiation 
therapy and, chemotherapy [1,2]. Chemotherapy uses anticancer drugs 
that target rapidly dividing cells, including but not exclusively cancer 
cells. Because they are distributed throughout the body and not 
localized to the cancer cells, these drugs affecting the normal cells as 
well [3]. Most of the chemotherapeutic agents, which have the lack of 
specific targets for cancer treatment, lead to increase toxicities of 
normal tissues so that many patients experience the classic symptoms, 
such as alopecia, gastrointestinal symptoms, and myelosuppression 
[4,5]. Therefore, a dramatic shift has taken place in cancer therapy 
from chemotherapy to targeted therapy [6]. The term ‘targeted 
therapy’ refers to a new generation of cancer therapy that interferes 
with a biomarker or specific target that is related to tumor growth or 
progression [7]. These strategies are aimed at preferentially killing 
cancer cells without exhibiting any significant toxic effect on normal 
cells[8]. The targeted therapy includes targeted radionuclide therapy, 
photodynamictherapy and immunotherapy [9]. In particular, targeted 
therapy involved the use ligands that show high-affinity for a cancer 
biomarker and directly interact with the cancer cells, functioning as 
carriers [10]. The molecules for targeted therapy consist of target 
specific ligands including small molecules, peptides and antibodies 
[11]. Moreover, high selectivity, stability and ability for internalization 
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of ligands are important for targeted therapy.
2. Tumor-induced angiogenesis
  Biomarkers capable of improving therapeutic response and targeting 
cancer play a key role in the targeted therapy [12]. Because cancer 
biomarkers are substances or processes that indicate the presence of 
cancer in the body, they can be associated with “hallmarks of cancer” 
[13]. Hanahan and Weinberg have categorized hallmarks of cancer, 
which include unlimited proliferative potential, environmental 
independence for growth, evasion of apoptosis, angiogenesis, invasion 
,and metastasis to different parts of the body (Figure 1) [14]. Based 
on an understanding of proposed hallmarks of cancer, this study 
focused on tumor induced-angiogenesis and its biomarker. 
Figure 1. The hallmark of cancer [14]
3
  Angiogenesis is a process of forming new blood vessels from 
existing ones and an essential mechanism to supply sufficient oxygen 
and nutrients for tumor growth, invasion and metastasis [15]. 
Tumor-induced angiogenesis is a complex events related with various 
growth factors, cellular receptors and adhesion molecules [16]. It is 
primarily regulated by vascular endothelial growth factor and cell 
adhesion receptor integrins [17]. Integrins, comprising α and β 
transmembrane subunits, interact with activated endothelial cells 
[18,19]. Particularly, integrin αvβ3 is overexpressed by activated 
endothelial cells during tumor growth and are located at the surface 
of angiogenic blood vessels on various tumors such as ovarian cancer, 
glioblastoma, breast cancer and melanoma (Figure 2) [20,21]. The 
high expression of integrin αvβ3 on new blood vessels for various 
tumor promises to be promising biomarker for targeted therapy 
[22,23].
Figure 2. Tumor induced angiogenesis [20,21]
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3. Integrin-binding peptide for tumor imaging
  The tripeptide sequence of arginine-glycine-aspartic acid (RGD) 
derivative is well known for ligand for binding integrin αvβ3 which 
plays a key role in modulating tumor angiogenesis [24,25]. While
linear RGD peptide are highly susceptible to chemical decomposition, 
numerous studies have reported that the cyclic RGD peptide are 
highly stable in vivo and show high affinity for stability for targeting 
receptors (Figure 3) [26]. Because cyclic peptides has rigidity by 
cyclization, it is generally more stable and specific to integrin αvβ3
than linear [27]. In particular, cyclic peptide c(RGDfK), obtained from 
cyclization of a linear RGD pentapeptide containing an unnatural 
D-phenylalaine (D-Phe), is commonly used as ligand [28,29]. 
  Multimeric cyclic RGD peptides, which have multiple cyclic RGD 
peptides, have been reported to show enhanced in vitro binding 
affinity for integrin αvβ3 on cancer cells (Table 1) [30,31].
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Figure 3. Structure of cyclic RGD peptides
Table 1. IC50 values of reported multimeric cyclic RGD peptides [30]
Compound IC50 (nM)
c(RGDyK) 458 ± 45
HYNIC-P-RGD 452 ± 11
HYNIC-RGD2 112 ± 21
HYNIC-P-RGD2 84 ± 7
HYNIC-RGD4 7 ± 2
The high cell-binding affinity of multimeric RGD peptide could be 
explained by endocytosis of ligand-bound integrin αvβ3 [32]. 
Interactions between integrin αvβ3 and RGD peptide could provide 
higher cellular uptake through the integrin-dependent endocytosis 
pathway [33]. 
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  Endocytosis of integrin means an internalization of receptors from 
the plasma into an internal membrane [34]. Generally, there are two 
types of pathways associated with the internalization of integrin [35]. 
One is a clathrin-mediated endocytosis and the other is a 
clathrin-independent endocytosis [36]. Integrin αvβ3 primarily 
internalized via clathrin-dependent endocytosis, which is initiated from 
clustering of integrin αvβ3 [37].
  After the RGD peptide binds to its receptor, ligand-bound integrin 
begin to form a cluster [38]. The clusters of integrin αvβ3 at ligand 
binding sites stabilized by cytoplasmic adhesion proteins that crosslink 
the integrin cytoplasmic tails plus connect the clusters to the cell 
cytoskeleton (Figure 4) [39]. This stabilized state, which is gathering 
of integrins, can accelerate process of endocytosis. Therefore, the 
clusters appear to be very important elements in many cellular 
processes and can be considered as a critical functional module. 
Besides, the clustering of receptors has obvious the advantage for the 
increased endocytosis of ligand-bound integrin αvβ3 [40].
  Several studies have proved this process that multimeric RGD 
peptides were internalized into cancer cell by receptor clustering and 
subsequent endocytosis [41,42]. From in vitro cell assay, monomeric 
cyclic RGD peptides were internalized independent of integrin αvβ3, 
whereas multimeric cyclic RGD peptides were internalized with their 
receptor via clustering of integrins [41,42]. Multimeric cyclic RGD 
peptides more strongly bound to integrin αvβ3 and more efficiently 
co-internalized with the receptor via clustering of integrins [41,42].
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Figure 4. Cluster and endocytosis of ligand-bound intergrin αvβ3 [39].
   Although multimeric RGD peptides had a significantly high 
cell-binding affinity for tumor, some in vivo studies shown multimeric 
concept has rapid excretion on tumor [43,44]. Wu and colleagues 
synthesized 18F-FPRGD2 (cyclic RGD dimer) and 18F-FPRGD4 (cyclic 
RGD tetramer) and compared their the tumor targeting efficacy and in 
vivo kinetics [43]. Results of in vivo micro PET study showed that 
the tumor uptake of 18F-FPRGD4 was higher than that of 
18F-FPRGD2 at all time points in the U87-MG xenograft model but 
the tumor uptake of both ligands reduced to half of the initial uptake 
after 2 h [43]. Lee et al. synthesized 99mTc-IDA-D-[c(RGDfK)]2 as 
radiotracer for SPECT/CT imaging. This ligand has high uptake and 
selectivity for several tumors and diseases related with infarction. 
However, it also has short half-life (122.7 min) for tumor uptake 
[44].  
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  Furthermore, studies that applied multimeric cyclic RGD peptide to 
targeted cancer therapy, suggested that fast washout on tumor affected 
the efficacy of therapy [45,46].
  Janssen and co-workers firstly investigated the effects of integrin αv
β3 targeted radionuclide therapy with 
90Y-DOTA-E-[c(RGDfK)]2 in an 
ovarian carcinoma-bearing mouse model [41]. Tumor growth was 
inhibited by a single injection of 90Y-DOTA-E-[c(RGDfK)]2 [45]. 
However, considerable uptake in non-target organs such as spleen, 
liver, and kidney was observed, and multiple injections and high dose 
were required to enhance the therapeutic efficacy [45]. In the 
following study, both 90Y-DOTA-RGD4 and 90Y-DOTA-3PRGD2 
induced inhibition of tumor growth in the U87-MG-bearing mouse 
model [46].  However, high dose or multiple injections of ligands 
were still required to achieve maximum therapeutic efficacy due to 
rapid washout of tumor uptake [46].
  One of the reasons for a fast washout at the tumor site is that 
multimeric cyclic RGD peptides could not simultaneously bind integrin 
αvβ3 under in vivo environments (Figure 5). There are various factors 
such as blood pressure, the density of integrin αvβ3 and pH that 
influence the ligand-receptor interaction in the cancer 
microenvironments. If multimeric cyclic RGD peptides were difficult 
to bind to multiple integrin αvβ3 simultaneously, it would not show 
the advantages of multimeric effect, such as enhanced binding affinity 
and retention on cancer [47,48]. Moreover, receptor clustering and 
endocytosis of ligand-bound integrin would not be favored as well. 
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Therefore, the new strategy is required to ensure strong binding 
with integrin αvβ3 and clustering under in vivo environments. This 
study designed the method, which induces in vivo clustering of 
intergrin αvβ3 by using intermolecular conjugation of cyclic RGD 
peptides. 
Figure 5. Schematic illustration of the interactions between mutimeric cyclic 
RGD peptide and integrin αvβ3.  (A) The multimeric cyclic RGD peptides 
bind integrin αvβ3 at the same time. The process of clustering and 
endocytosis of ligand-bound receptor could start from this state. (B) The two 
RGD motifs, which is named cyclic RGD dimer is not enough for 
simultaneous integrin αvβ3 binding. 
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4. In vivo intermolecular conjugation 
  For in vivo intermolecular conjugation, click reaction was 
considered in this study. Click reaction, first described by Kolb, 
involves  copper-catalysed formation of 1,2,3-triazole by [2+3] 
cycloaddition of terminal alkynes and azides [49,50]. Although this 
method is an attractive synthetic process because of its convenient, 
cytotoxicity of copper is an obstacle for its in vivo application 
[51,52]. 
  In the following study, the Bertozzi group developed the 
copper-free click reactions, which was referred to as strain promoted 
azide-alkyne cycloaddition (SPAAC) of azide-azadibenzocyclooctyne 
(ADIBO) [53,54]. Recently, Inverse Electron Demand Diels–Alder 
(IEDDA) of tetrazine-trans-cyclooctene (TCO) with fast kinetics was 
reported (Figure 6) [55]. The copper-free click reaction carried out 
under aqueous condition at room temperature and is completed a short 
period [56]. Therefore, many groups adapted copper-free click reaction 
to in vivo system because of its high stability, reactivity ,and utility 
[57]. For these reasons, copper-free click reaction were used for in 
vivo intermolecular conjugation in this study.
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Figure 6. Copper free Click reaction.
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5. Aim of this study
  This study was aimed at developing a strategy to ensure that the 
ligands are strongly bound to the receptors and that the ligand bound 
receptors form clusters. For this, in situ intermolecular click reaction 
between different RGD peptides that are bound to their tumor-specific 
receptors, resulting in the formation a 'Dual Bioorthogonal Clasp
(DBC)' was designed. This was envisaged to strengthen the 
ligand-receptor interactions and induce endocytosis of ligand-bound 
integrin αvβ3 into tumor cells to enhance tumor uptake of the peptide 
as well as increase the retention time at the cancer site (Figure 7). 
  For this method, two different cyclic RGD peptides containing click 
moiety for intermolecular conjugation were designed as integrin 
binding ligands. In addition, the radiolabeled RGD peptide was 
prepared to measure in vivo kinetics by single photon emission 
computed tomography (SPECT) imaging using the radioisotope 123I or 
125I [APPENDIX 1]. The internalization of integrin αvβ3 receptors on 
tumor cells was evaluated by fluorescence resonance energy transfer 









1. General experimental section
  All commercial reagents and solvents were used without further 
purification unless otherwise specified and  were purchased from 
Sigma-Aldrich, Tokyo Chemical Industry Co. (TCI), Alfa Aesar and 
Futurechem. Electrospray mass spectrometry (ESI-MS) was performed 
on a LC/MS spectrometer (Agilent 6130 Series). Radio-TLC on Merck 
F254 silica plate was analyzed by using a Bioscan radio-TLC scanner. 
All radioactivities were measured using a VDC-505 activity calibrator 
from Veenstra Instruments. [123I]NaI was purchased from Korea 
Institute of Radiological and Medical Sciences (KIRAMS). The 
purification by HPLC was carried out on Agilent equipped with a UV 
detector (wavelength set at 214 or 254 nm) and a gamma-ray detector 
(Bioscan) using a semi-preparative column (Waters, Xterra RP-18, 10 
μm, 10 × 250 mm). All solvents (J. T. Baker, U. S.) were used for 
HPLC purification after membrane filtering (Whatman, 0.22 µm). The 
column was eluted with a solvent mixture of acetonitrile and water 
containing 0.1% formic acid. The HPLC eluent started with 5% 
acetonitrile contained 0.1% formic acid and the ratio was increased 
from 40% acetonitrile to 60% containing 0.1% formic acid over 30 
min at a flow rate of 3 mL/min.
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Cell culture: U87-MG (human gliblastoma) was grown in Dulbecco's 
Modified Eagle's Medium (DMEM). A549 (human lung 
adenocarcinoma)  was maintained in RPMI1640. All media were 10% 
fetal bovine serum (FBS) and 1% antibiotics (10,000 unit/mL of 
penicillin and 10,000 μg/mL of streptomycin) / antimycotics (25 μ
g/mL of Fungizone®). Cultures were maintained at 37 ℃ in a 
humidified 95% air and 5% CO2 atmosphere [44].
U87-MG tumor xenografted mouse model: All animal experiments 
were conducted under a protocol approved by SNUBH Institutional 
Animal Care and Use Committee (IACUC). BLAB/c athymic mice 
(OrientBio, male, 6-7 weeks) were used in all experiments. U87-MG 
cells were cultured for 2–3 days, without changing the media, and 
harvested with 0.25% trypsin-EDTA solution. 1⨯107 U87-MG cells in 
100 μL  of PBS (pH 7.4) were injected subcutaneously in the right 
thigh of each mouse. Ex vivo biodistribution and in vivo animal 
SPECT/CT imaging studies conducted when the each tumor reached a 
long diameter of 1 cm at 2-3 weeks after implanting of tumor cells 
in nude mice.
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2. Synthesis of RGD peptides
NH2-D-[c(RGDfK)]2 (1)
A solution of N-(tert-butoxycarbonyl)-L-aspartic acid (13 mg, 0.06 
mmol), HOBT (32 mg, 0.24 mmol), HBTU (91 mg, 0.24 mmol) in 
DMF (2 mL) was added a mixture of c(RGDfK)-NH2 (200 mg, 0.20 
mol) and DIEA (83 μL, 0.48 mmol) in DMF (2 mL). The mixture 
was stirred at room temperature for 18 h. After concentration under 
reduced pressure, the crude mixture was purified with flash column 
chromatography (CH2Cl2:MeOH, v/v = 90:10). The resulting solution 
was dried under reduced pressure, BocNH-D-[c(RGDfK)]2 (80 mg, 
66%) was obtained as pale yellow semi-solid: MS (ESI) m/z 2020.1 
(M + H)+, 1010.5 (M + 2H)2+
  In order to removed the Boc group, A obtained 
BocNH-D-[c(RGDfK)]2 (70 mg, 0.03 mmol) was treated with 4 mL 
of solution mixture with trifluoroacetic acid, triisopropylsilane and 
distilled water (v/v/v = 95 : 5 : 5). The solution was stirred at room 
temperature for 18 h. The solvent was removed under reduced 
pressure. The mixture was dissolved with methanol (2 mL) and added 
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with excess diethyl ether (20 mL), then white solid appeared. The 
solid was filtered, washed with diethyl ether and dried in vacuum, it 
gave NH2-D-[c(RGDfK)]2, (1, 35 mg, 89%) as pale yellow solid: 
MS (ESI) m/z 1304.6 (M + H)+, 652.5 (M + 2H)2+
BocNH-D-[c(RGDyK)]-COOH (2)
  A solution of N-(tert-butoxycarbonyl)-L-aspartic acid 4-benzyl ester 
(50 mg, 0.15 mmol), HOBT (42 mg, 0.31 mmol), HBTU (118 mg, 
0.31 mmol) in DMF (3 mL) was added to a mixture of 
c(RGDyK)-NH2 (200 mg, 0.20 mmol) and DIEA (81 μL, 0.46 mmol) 
in DMF (3 mL). The mixture was stirred at room temperature for 4 
h. The solvent was removed and dissolved with methanol (6 mL) 
then added excess diethyl ether (50 mL) to get the solid. The solid 
was filtered and washed with ether. The resulting solid was dissolved 
in a solvent mixture of water and CH3CH (v/v = 95/5) and separated 
by a semi-preparative HPLC system. The expected product was 
collected at 27.1 min. After the resulting solution was dried under 
reduced pressure, it gave BocNH-D-[c(RGDyK)]-COOBn (100 mg, 
72%) as pale yellow solid: MS (ESI) m/z 925.10 (M + H)+
  A obtained BocNH-D-[c(RGDyK)]-COOBn (100 mg, 0.11 mmol) 
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was dissolved in MeOH/DMF (v/v = 90/10, 5 mL) and treated with 
Pd/C (34 mg, 0.03 mmol). The mixture was stirred under H2 gas at 
room temperature for 18 h. The resulting solution was filtered on 
celite and the filtrate was concentrated under reduced pressure. The 
solid was dissolved with methanol (6 mL) and added with excess 
diethyl ether (50 mL) to gain solid. The solid was filtered and 
washed with diethyl ether then dried in vacuo. The desired 
BocNH-D-[c(RGDyK)]-COOH (2, 82 mg, 90%) was obtained as pale 
yellow solid: MS (ESI) m/z 835.20 (M + H)+
NH2-D-[c(RGDyK)]-[c(RGDfK)] (3)
  A solution of compound 2 (80 mg, 0.09 mmol), HOBT (26 mg, 
0.19 mmol), HBTU (72 mg, 0.19 mmol) in DMF (2 mL) was added 
with a mixture of c(RGDfK)-NH2 (69 mg, 0. 11 mmol) and DIEA 
(48 μL, 0.28 mmol) in DMF (2 mL). The mixture was stirred at 
room temperature for 4 h. The solvent was removed and dissolved 
with methanol (5 mL) added excess diethyl ether (30 mL) to get the 
solid. The solid was filtered and washed with ether then dissolved in 
a solvent mixture of water and CH3CH (v/v = 95/5). The solution 
was separated by a semi-preparative HPLC system and the expected 
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product was collected at 25.1 min. After the resulting solution was 
dried under reduced pressure, it gave BocNH-D-c(RGDyK)-c(RGDfK)
(79 mg, 62%) as pale yellow solid: MS (ESI) m/z  1420.6 (M + H)+, 
710.5 (M + 2H)2+
  A obtained BocNH-D-c(RGDyK)-c(RGDfK) (70 mg, 0.04 mmol) 
was dissolved in TFA/distilled water (v/v = 95/5, 2 mL) and stirred 
at room temperature for 4 h. The solvent was removed under reduced 
pressure and dissolved with methanol then added excess diethyl ether 
to get white solid. The solid was filtered and washed with diethyl 
ether. After the solid was dried in vacuum, it gave compound 
NH2-D-[c(RGDyK)]-[c(RGDfK)], (3, 47 mg, 90%) as pale yellow 
solid: MS (ESI) m/z 1320.6 (M + H)+, 660.5 (M + 2H)2+
ADIBO-D-[c(RGDfK)]2 (4)
  The compound 1 (30 mg, 0.02 mmol) was dissolved in 2 mL of a 
solution mixture with DMF and water (v/v = 1/1) in a vial and 
added with azadibenzocyclooctyne-N-hydroxysuccinimidyl ester (ADIBO 
analog, 42 mg, 0.09 mmol). The mixture was stirred at room 
temperature for 3 h. The solution was diluted with water. The 
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solution was separated by a semi-preparative HPLC system. The 
expected product (ADIBO-D-[c(RGDfK)]2, 4) was collected at 25.4 
min. After the resulting solution was dried under reduced pressure, it 
gave compound 7 (20 mg, 60%) as white solid: MS (ESI) m/z 1662.2 
















  The compound 3 (40 mg, 0.03 mmol) was dissolved in 2 mL of 
solvent mixture with DMF and water (v/v = 1/1) in a vial and added 
succinimidyl 4-azidobutyrate (16 mg, 0.07 mmol). After the mixture 
was stirred at room temperature for 3 h,  the solution was diluted 
with water and followed by sby a semi-preparative HPLC purification. 
The desired N3-butyl-D-[c(RGDyK)]-[c(RGDfK)] (5) was collected at 
21.1 min. After the resulting solution was dried under reduced 
pressure, it gave compound 4 (26 mg, 60%) as white solid: MS (ESI) 
m/z 1431.6 (M + H)+, 716.3 (M + 2H)2+
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ADIBO-D-(NH2)-D-[c(RGDfK)]2 (6)
  The compound 1 (40 mg, 0.03 mmol) was dissolved in DMF/DW 
(v/v = 1/1, 1 mL) in vial and added ADIBO-Asp(Fmoc)-NHS (42 
mg, 0.06 mmol). The mixture was stirred at room temperature for 3 
h. After removing the solvent, the solution was diluted with water 
and separated by a semi-preparative HPLC system. The desired 
compound was collected at 27.2 min. The solid was added 20% 
piperidine in DMF and was stirred for 4 h at room temperature. The 
solvent was removed under reduced pressure and dissolved with 
methanol then added excess diethyl ether to get white solid. The solid 
was filtered and washed with diethyl ether. After the resulting 
solution was dried under reduced pressure, it gave 
ADIBO-D-NH2-D-[c(RGDfK)]2,  (6, 26 mg, 62%) as white solid: MS 
(ESI) m/z 1677.8 (M + H)+, 834.4 (M + 2H)2+.
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N3-K-D-[c(RGDfK)]-[c(RGDyK)] (7)
The compound 3 (30 mg, 0.02 mmol) was dissolved in 1 mL of 
solvent mixture with DMF and water (v/v = 1/1) in a vial and added 
to N3-Lys(Boc)-NHS (17 mg, 0.05 mmol). The mixture was stirred at 
room temperature for 3 h. After removing solvent, the reaction 
mixture was diluted with water and separated by a semi-preparative 
HPLC system. The desired compound was collected at 23.1 min. The 
solid was treated with TFA and then was stirred for 4 h at room 
temperature. After removing TFA under reduced pressure, the reaction 
mixture dissolved with methanol then added excess diethyl ether to 
get white solid. After the resulting solution was dried under reduced 
pressure, it gave N3-K-D-[c(RGDfK)]-[c(RGDyK)] (7, 26 mg, 61%) as 
white solid: MS (ESI) m/z 1474.6 (M + H)+, 737.5 (M + 2H)2+
TCO-K-NH2-D-[c(RGDfK)]2 (8)
The compound 1 (40 mg, 0.03 mmol) was dissolved in 1 mL of 
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solvent mixture with DMF and water (v/v = 1/1) in vial and added 
TCO-Lys(Boc)-NHS (34 mg, 0.07 mmol). The mixture was stirred at 
room temperature for 3 h. After removing solvent, the reaction 
mixture was diluted with water and separated by a semi-preparative 
HPLC system. The desired compound was collected at 26.6 min. The 
solid was treated with TFA and then was stirred for 4 h at room 
temperature. After removing TFA under reduced pressure, the reaction 
mixture dissolved with methanol then added excess diethyl ether to 
get white solid. After the resulting solution was dried under reduced 
pressure, it gave TCO-K-NH2-D-[c(RGDfK)]2 (8, 21 mg, 44%) as 
white solid: MS (ESI) m/z 1583.8 (M + H)+, 192.2 (M + 2H)2+.
Tz-K-D-[c(RGDfK)]-[c(RGDyK)] (9)
The compound 3 (20 mg, 0.03 mmol) was dissolved in 1 mL of 
solvent mixture with DMF and water (v/v = 1/1) in a vial and added 
to tetrazine-Lys(Boc)-NHS (43 mg, 0.07 mmol). The mixture was 
stirred at room temperature for 3 h. After removing solvent, the 
reaction mixture was diluted with water and separated by a 
semi-preparative HPLC system. The desired compound was collected 
at 24.8 min. The solid was treated with TFA and then was stirred for 
4 h at room temperature. After removing TFA under reduced pressure, 
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the reaction mixture dissolved with methanol then added excess 
diethyl ether to get white solid. After the resulting solution was dried 
under reduced pressure, it gave product 
Tz-K-D-[c(RGDfK)]-[c(RGDyK)] (9, 26 mg, 61%) as white solid: MS 
(ESI) m/z 1730.8 (M + H)+, 866.5 (M + 2H)2+
N3-butyl-D-[c(RGDfK)]-[c(RGDy(I)K)] (10)
  The iodination of compound 5 was prepared according to literature 
[58]. The solution of compound 5 (10 mg, 7.00 µmol) in water (0.5 
mL) was treated N-iodosuccinimide (0.3 mg, 1.40 µmol) in CH3CH 
(0.5 mL). The mixture was stirred at room temperature for 15 min. 
The solution was diluted with water and followed by a 
semi-preparative HPLC purification. The expected product 
((N3-butyl-D-[c(RGDfK)]-[c(RGDyK)]) was collected at 22.8 min. 
After the resulting solution was dried under reduced pressure, it gave 
compound 10 (1.2 mg, 12%) as white solid: MS (ESI) m/z 1557.4 




































  The solution of compound 7 (2 mg, 1.20 µmol) in 0.5 mL of 
solvent mixture with EtOH and water (v/v = 1/1) was treated 
compound 3 (1.7 mg, 1.20 µmol) in 0.5 mL of solvent mixture with 
EtOH and water (v/v = 1/1). The mixture was stirred at room 
temperature for 3 h . The solution was diluted with water and 
followed by the HPLC purification. The product was collected at 22.1 
min. After the resulting solution was dried under reduced pressure, it 
gave ADIBOT-D2-[c(RGDy(I)K)]-[c(RGDfK)]3 (11, 2 mg, 52%) as 
white solid: MS (ESI) m/z 1610.5 (M + 2H)2+, 1073.7 (M + 3H)3+
805.5 (M + 4H)4+
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3. Fluorescent dyes conjugation with RGD peptides
N3-K-FITC-D-[c(RGDyK)]-[c(RGDfK)] (12)
The compound 7 (5 mg, 2 μmol) was dissolved in PBS buffer (0.5 
mL, pH 7.5) in a vial and added FITC-NCS (2 mg, 4 μmol). The 
mixture was stirred at room temperature for 1 h. The solution was 
diluted with water and separated by gel filteration column. After the 
resulting solution was dried under reduced pressure, it gave 
N3-K-FITC-D-[c(RGDyK)]-[c(RGDfK)] (12, 3 mg, 72%) as yellow 
solid: MS (ESI) m/z 1862.6 (M + H)+, 932.5 (M + 2H)2+.
ADIBO-D-TRITC-D-[c(RGDfK)]2 (13)
   The compound 6 (5 mg, 2 μmol) was dissolved in PBS buffer 
(0.5 mL, pH 7.5) in vial and added TRITC-NCS (2 mg, 4 μmol). 
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The mixture was stirred at room temperature for 1 h. The solution 
was diluted with water and separated by gel filteration column. After 
the resulting solution was dried under reduced pressure, it gave 
ADIBO-D-(TRITC)-D-[c(RGDfK)]2 (13, 3.1 mg, 75%) as pink solid: 




  The solution of compound 12 (2 mg, 1.00 µmol) in 0.5 mL of 
solvent mixture with EtOH and water (v/v = 1/1) was treated 
compound 13 (2.1 mg, 1.00 µmol) in 0.5 mL of solvent mixture with 
EtOH and water (v/v = 1/1). The mixture was stirred at room 
temperature for 3 h. The solution was diluted with water and 
separated by gel filteration column. After the resulting solution was 
dried under reduced pressure, it gave 14 (2.8 mg, 76%) as pink solid: 




  The compound 9 (5 mg, 3 μmol) was dissolved in PBS buffer (0.5 
mL) in a vial and added FITC-NCS (2.6 mg, 6 μmol). The mixture 
was stirred at room temperature for 1 h. The solution was diluted 
with water and separated by gel filteration column. After the resulting 
solution was dried under reduced pressure, it gave 
Tz-K-FITC-D-[c(RGDyK)]-[c(RGDfK)] (15, 3 mg, 72%) as yellow 
solid: MS (ESI) m/z 2120.8 (M + H)+, 1060.9 (M + 2H)2+.
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TCO-K-TRITC-D-[c(RGDfK)]2 (16)
   The compound 8 (5 mg, 3 μmol) was dissolved in PBS buffer 
(0.5 mL) in vial and added TRITC-NCS (2.6 mg, 6 μmol). The 
mixture was stirred at room temperature for 1 h. The solution was 
diluted with water and separated by gel filteration column. After the 
resulting solution was dried under reduced pressure, it gave 16 (4.8 
mg, 80%) as pink solid: MS (ESI) m/z 2028.9 (M + H)+, 1014.5 (M 
+ 2H)2+, 676.6 (M + 3H)3+
Dihydropyrazine-K2-FITC-TRITC-D2-c(RGDyK)-[c(RGDfK)]3 (17)
  The solution of compound 15 (2 mg, 1.00 µmol) in 0.5 mL of 
solvent mixture with EtOH and water (v/v = 1/1) was treated 
compound 16 (2 mg, 1.00 µmol) in 0.5 mL of solvent mixture with 
EtOH and water (v/v = 1/1). The mixture was stirred at room 
temperature for 3 h. The solution was diluted with water and 
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separated by gel filteration column. After the resulting solution was 
dried under reduced pressure, it gave 17 (2.8 mg, 69%) as pink solid: 
MS (ESI) m/z 2075.8 (M + 2H)2+, 1384.2 (M + 3H)3+ 1038.4 (M + 
4H)4+
4. Radioiodo-labeling of RGD peptides
N3-butyl-D-[c(RGDfK)]-[c(RGDy(
123I)K)] ([123I]10)
  To [123I]NaI solution (740 MBq) in 1 M NaOH, 1 M HCl (50 µL) 
was added to adjust pH 6.5. The solution of precursor (5) (0.2 mg) 
in water (100 µL) and chloramine-T in water (100 µL) was added to 
[123I]NaI solution. The reaction mixture was stirred at room 
temperature for 10 min. The crude mixture was diluted with excess 
water and passed through into plus tC18 Sep-Pak then eluted with 
90% methanol-water (2 mL). The resulting solution was purified with 
semi-preparative HPLC system. The expected product [123I]10 was 
collected at 21.5 min and radiochemical yield was 34.0 ± 6.5%, 
decay-corrected. The obtained solution was loaded into plus tC18 





  The solution of [123I]10 (185 MBq) in water (200 µL) was treated 
to ADIBO-D-[c(RGDfK)]2 (4) in ethanol (200 µL). This mixture was 
stirred with bubbling nitrogen at 36 oC for 40 min. The crude 
mixture was diluted with water and purified with semi-preparative 
HPLC system. The expected product [123I]11 was collected at 17.5 
min and radiochemical yield was 59.3 ± 4.0%, decay-corrected. The 
resulting solution was loaded into plus tC18 Sep-Pak and exchanged 
to 10% ethanol-water.
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5. In vitro evaluation of RGD peptides
Human serum stability
  The stability of [123I]10 and [123I]11 was analyzed by monitoring 
the Radio-TLC. Human whole blood was centrifuged at 3500 rpm for 
5 min, and the supernatant was collected into new tube. An aliquot 
(3.7 MBq) of 123I-N3-RGD dimer and 
123I-Tz-RGD tetramer in 10% 
ethanol-saline (0.1 mL) was added to human serum (0.5 mL) and the 
mixture incubated at 37 oC for 4 h. At each time point (10, 30, 60, 
120, and 240 min), the sample (0.1 mL) was taken and added to 
acetonitrile (0.1 mL). After vortexing (30 s), the mixture was 
centrifuged at 3,500 rpm for 5 min. The obtained supernatant was 
analyzed by radio-TLC using 100% acetone as the developing 
solvents. Rf value was 0 for 
123I-N3-RGD dimer and 
123I-Tz-RGD 
tetramer and 0.9 for free iodine, respectively.
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Flow cytometric assay
  Cells were detached with 0.05 M trypsin/EDTA solution and 
washed with cold PBS (10 mM) twice. Cells were prepared in FACS 
tube (BD bioscience) at a concentration of 5 x 105 cells/ 100 μL of 
10 mM PBS containing 1% bovine serum albumin (BSA, 
Sigma-Aldrich). The cells were incubated with anti-integrin alpha V 
beta 3 (Abcam, FITC-conjugated) or the isotype control antibody 
(mouse IgG1 kappa [MOPC-21] FITC, Abcam) for 1 h at 4℃ with 
constant shaking using thermomixer (Eppendorf). After incubation, the 
stained cells were washed twice with cold PBS containing 1% BSA 
and analyzed using Guava® easy Flow Cytometer and InCyte™ 
GuavaSuite Software (Merck).
Binding assay 
  The receptor binding affinity studies of [123I]10 and [123I]11 were 
performed using 125I-c(RGDyV) as the integrin-specific radio-ligand 
[36]. The 100 µL of a cell suspension in microcentrifuge tubes were 
incubated with 125I-c(RGDyV) (0.037 MBq/tube) in the presence of 
increasing concentrations of I-N3-RGD dimer and I-Tz-RGD tetramer. 
The tubes were centrifuged at 2,000 rpm at 4 oC, respectively. 
Centrifuged cell pellets were washed three times with cold PBS (1 
mL). The radioactivity was determined using a gamma counter 
(Wizard 1480, wallac). 
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FRET microscopy
  U87-MG cells were plated on glass bottom confocal dish (SPL Life 
Science) round cover glasses (seeding density of 1 × 106 cells/3 mL 
of complete DMEM). Cells were grown for 48 h at 37℃ with 5 % 
CO2 atmosphere. The medium discarded and the cells were rinsed 
with 2 mL of PBS buffer for twice. Cells were treated with both of 
12 (50 μM) and 13 dimer (50 μM) or only 14 (50 μM) or blocking 
and incubated for 2 h at 37 oC. After incubation, cells were washed 
three times with 2 mL of cold PBS. 4% paraformaldehyde was added 
in each dish for fixation. Fixation was performed  for 1 h at room 
temperature in the dark condition. The confocal imaging and FRET 
measurements were carried out on an inverted confocal microscope 
(Nikon A1 Rsi). Two different band path filters, namely, 490/525,  
and 557/576 nm, to collect the emission signal from FITC and FRET, 
respectively, upon irradiation with the same excitation laser (490 nm 
for FITC excitation, 576 nm for TRITC emission).
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6. Ex/In vivo evaluation of RGD Peptides
Ex vivo biodistribution 
Ex vivo biodistribution studies were performed in U87-MG tumor 
bearing mouse model. The mice were injected with [123I]10 and 
[123I]11 and using sequential targeting (0.74 MBq, 200 μL in saline) 
into the tail vein, sacrificed at the indicated time points (n = 4, 10, 
30, 60 and 120 min). Blood, tumor, and normal organs (heart, liver, 
lung, spleen, kidneys, small intestine, large intestine, muscle, thyroid, 
brain and femur) were extracted and measured for radioactivity using 
a gamma counter. Data was presented as the percentage of the 
injected dose per gram of tissue in comparison with samples of a 
standard dilution of the initial dose (%ID/g).
Small Animal SPECT/CT Imaging
  High-resolution SPECT scans of each mouse for 90 or 120 min 
after the intravenous injection of radiotracers  (18.5 MBq, n = 3). 
Mice were placed in a prone position on the bed under anesthesia 
with 2% isoflurane. Whole body mouse SPECT/CT imaging perforemd 
on a Nano SPECT/CT tomograph (Bioscan) equipped with 4 NaI 
detectors and fitted with 1.4 mm mouse wholebody multi-pinhole 
collimator with 9 pinholes (full width at half maximum ≤ 1.2 mm). 
A total of 14 projections were acquired in a 256 ⨯ 256 acquisition 
matrix with a 15 s per projection.  Images were reconstructed using a 
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2D ordered-subset expectation maximization algorithm (9 iteration). 
Cone-beam CT images were acquired (180 projection, 500 
ms/projectoin, 45 kVp) before SPECT imaging. Co-registration of 
SPECT and CT images was performed using InvivoScope software 
(Bioscan). The SPECT imaging was followed by CT image acquisition 
with the animal in exactly the same position. 
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RESULTS
1. Preparation of RGD peptides
  The dimeric RGD peptides (NH2-D-[c(RGDfK)]2 (1) and 
NH2-D-[c(RGDyK)]-[c(RGDfK)] (3)) were designed as ligands for 
integrin αvβ3, based on the previous studies [44]. The functional 
groups for azide/ADIBO and tetrazine/TCO click reaction were 
incorporated into the peptides as shown in the schemes below (Figure 
8, 9). The 3 was designed to contain a cyclic RGDyK for 
radiolabeling, which includes a tyrosine residue to label with 123I or 
131I.
  NH2-D-[c(RGDfK)]2 (1) was synthesized by amide condensation of 
N-(tert-butoxycarbonyl)-L-aspartic acid and the protected 
c(RGDfK)-NH2 peptide followed by deprotection of Pbf and tert-butyl 
groups. NH2-D-[c(RGDyK)]-[c(RGDfK)] (3) was obtained from amide 
coupling of N-(tert-butoxycarbonyl)-L-aspartic acid 4-benzyl ester and 
c(RGDyK)-NH2 followed by the deprotection of the benzyl group in 
the presence of 10% palladium on charcoal under hydrogen 
atmosphere to get the intermediate (2). To make RGD dimer, amino 
group of c(RGDfK)-NH2 was linked with 
Boc-NH-D-[c(RGDyK)]-COOH (2), followed by the deprotection of 
Boc group. 
  The compounds 4, 6, and 8 was prepared by amide coupling 
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between 1 and ADIBO or TCO moiety and the compounds 5, 7, and 
9 was synthesized by amide condensation of azide or tetrazine moiety 
and 3. Especially, 6, 7, 8, and 9 included –NH2 group for 
conjugation with fluorescent dyes. All RGD peptides were purified by 
HPLC system with >98% purity and confirmed by LC-MS. 
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Figure 8. Synthesis of cyclic RGD peptides.
Figure 9. Synthesis of cyclic RGD peptides for click reaction
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Figure 10. Synthesis of fluorescent conjugated cyclic RGD peptides 
Figure 11. Radiolabeling of cyclic RGD peptides 
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2. Fluorescent dyes conjugated RGD peptides
   For the confocal imaging, two fluorescence dyes, FITC 
(fluorescein-isothiocyanate) and TRITC (tetramethylrhodamine) were 
conjugated to the peptides for in vitro FRET assays. After preparing 
NH2-D-[c(RGDfK)]2 (1) and NH2-D-[c(RGDyK)]-[c(RGDfK)] (3), 
aspartic acid or lysine residue of each RGD peptide was conjugated 
with a fluorescence dye (Figure 10).
  Then, FITC or TRITC conjugated RGD peptides (12-17) were 
synthesized by amide condensation of amine moiety of RGD peptides 
and isocyanate moiety of dyes. The fluorescent dye labeled RGD 
dimers were purified by size exclusion chromatography.
3. Radioiodo-labeled RGD peptides
  The N3-butyl-D-[c(RGDfK)]-[c(RGDy(I)K)] (10) as the cold standard 
were prepared according to reference [54]. In the presence of 5, 
N-iodosucciniimide (1.2 equiv.) in CH3CH (0.5 mL) was treated and 
the mixture was stirred at room temperature for 15 min. 
ADIBOT-D2-c(RGDy(I)K)-[c(RGDfK)]3 (11) was synthesized via click 
reaction between prepared 10 and 4. After the reaction, both 10 and 
11 were purified with a semi-preparative HPLC system.
  For the radiolabeling of 5, the precursor was mixed with [123I]NaI 
(740 MBq) and chloramine T (3.3 equiv.) as an oxidant (Figure 11). 
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The mixture was incubated at room temperature for 10 min. After 
incubation, the reaction mixture was purified by a semi-preparative 
HPLC system and the desired product ([123I]10) was obtained at 18.7 
min with 34.0 ± 6.5% radiochemical yields (n = 4, decay-corrected) 
and high purity (> 99%). The identity of the compound was 
confirmed by co-injection with a cold compound (Figure 12).
  To compare tumor uptake of new strategy, [123I]11 was prepared by 
using conjugation of [123I]10 and 4 (Figure 10). The reaction was 
carried out in ethanol/water (v/v = 1/1) at 36℃ for 1 h. The reaction 
mixture was purified by a semi-preparative HPLC system. The product 
([123I]11) was obtained at 15.4 min with adequate radiochemical yield 
(59.3 ± 4.0%, n = 3, decay-corrected) and high purity (>99%). The 
identity of the compound was confirmed by co-injection with a cold 
compound (Figure 13).
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Figure 12. HPLC profile for co-injection with [123I]10 and 10
Figure 13. HPLC profile for co-injection with [123I]11 and 11. 
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4. In vitro experimental results
In vitro intermolecular conjugation
  Before in vitro and in vivo analysis using U87-MG cells, reaction 
time of the click reaction was evaluated by using HPLC system. 
Moreover, reaction rate between azide-ADIBO pair and tetrazine-TCO 
pair was assessed to investigate the efficiency of the click moiety.
  A solution of N3-K-FITC-D-[c(RGDyK)]-[c(RGDfK)] (12) or 
Tz-K-FITC-D-[c(RGDyK)]-[c(RGDfK)] (15) in distilled water/PBS 
buffer (v/v =1/1) was treated with ADIBO-D-TRITC-D-[c(RGDfK)]2
(13) or TCO-K-TRITC-NH2-D-[c(RGDfK)]2 (16) for 40 min at room 
temperature. Aliquot of the reaction mixture was analyzed using an 
HPLC system at 0, 10, 20, 30, and 40 min (Figure 14). The results 
showed that the reaction time was shorter for tetrazine-TCO pair by 
approximately 10 min.
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Figure 14. Comparison with time of click reaction. (A) HPLC 
chromatograms during the click reaction with aizide and ADIBO moiety at 
0, 10, 20, 30, and 40 min. Identification of 12 (TR = 12.0 min), 14 (TR = 
12.7 min), 13 (TR = 13.5 min). (B) HPLC chromatograms during the click 
reaction with tetrazine and TCO moiety at 0, 10, 20, 30, and 40 min. 




  The stability of [123I]10 and [123I]11 was determined by radio thin 
layer chromatography using acetone as a developing solvent. [123I]10 
and [123I]11 were sufficiently stable in human serum at 36 oC for 4 
hours and only 4 % of [123I]10 and 7 % of [123I]11 were dissociated. 
These results indicate that radiolabeled RGD peptides would evaluate 
in vivo the expression level of integrin αvβ3 on tumor and in vivo 
intermolecular click reaction without degradation.
Integrin αVβ3 expression on U87-MG cells 
  Before performing the in vitro and in vivo analysis, the expression 
of integrin αVβ3 on U87-MGU87-MG cells was determined by flow 
cytometric assay. While integrin αVβ3 positively expressed on 
U87-MGU87-MG cells, it was not found on the negative control 
A549 cells (Figure 15). Thus, U87-MG cells were sufficiently suitable 
for in vitro and vivo experiments.
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Figure 15. Flow cytomtric analysis for integrin αVβ3 expression of A549 and 
U87-MG cell lines. Cells were incubated with isotype control antibody 
(black line histogram) or anti-integrin αVβ3 (gray filled histogram). Isotype 
antibody was used as a control. The mean of fluorescence intensities were 
12.69 (A549) and 55.50 (U87-MG), respectively. 
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In vitro binding affinity for integrin αVβ3
  The binding affinity of N3-butyl-D-[c(RGDfK)]-[c(RGDy(I)K)] (10) 
and ADIBOT-D2-c(RGDy(I)K)-[c(RGDfK)]3 (11) for integrin αvβ3 was 
determined in a competitive cell binding assay. Binding of 10 and 11
to integrin αvβ3 was competed by 
125I-c(RGDyV) in a 
concentration-dependent manner on U87-MG cells. The IC50 values of 
10 and 11 were 1.08 ± 0.08 nM and 0.52 ± 0.12 nM, respectively 
(Table 2). The binding affinity for integrin αvβ3 on U87-MG cells of 
11 (tetramer form) was slightly higher than that of 10 (dimer form). 
Table 2. Affinities (IC50, nM) for integrin αvβ3
a
aThe in vitro binding affinity (Ki, nM) was measured by competition 
with 125I-c(RGDyV) on U87-MG cells.
Compound IC50 (nM)
10 1.08 ± 0.08
11 0.52 ± 0.12
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In vitro blocking study
The blocking study, which can confirm the selectivity, performed on 
U87-MG cells by using confocal imaging (Figure 16). FITC 
conjugated RGD peptides (N3-K-FITC-D-[c(RGDyK)]-[c(RGDfK)] (12), 
and c(RGDyK) as blocker were prepared for in vitro cell assays. In 
the results, fluorescent signals of FITC were observed on cancer cell 
in treatment of 12 but, 12 blocking with c(RGDyK) not showed 
fluorescent signals. This results indicated that ligand for this study 
selectively bound to integrin αvβ3.
Figure 16. In vitro blocking study with c(RGDyK) on U87-MG cells. 
Condition; N3-K-FITC-D-[c(RGDyK)]-[c(RGDfK)] (12), 12 blocking 
with c(RGDyK)
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In vitro confocal microscopy imaging on U87-MG cells
FRET imaging, which can be an accurate measurement of molecular 
proximity at nanometer distances (1-10 nm), allows the detection of  
intermolecular conjugation. To identify intermolecular conjugation of 
RGD peptides on U87-MG cells, FITC or TRITC conjugated RGD 
peptides (N3-K-FITC-D-[c(RGDyK)]-[c(RGDfK)] (12),
ADIBO-D-TRITC-D-[c(RGDfK)]2 (13) and 
ADIBOT-K-D-FITC-TRITC-D2-c(RGDyK)-[c(RGDfK)]3 (14)) were 
prepared for in vitro FRET analysis. For the in vitro assay, three 
groups was considered: control, blocking and treatment group. The 
control group was treated with one of fluorescent conjugated RGD 
peptide (12 or 13). The pre-conjugated RGD peptide between 12 and 
ADIBO-NH2 (3-amino-1-(11,12-didehydrodibenz[b,f]azocin-5(6H)-yl)-1-
propanone) was treated as a dummy for blocking intermolecular 
conjugation, which could help identify FRET signals that indicate 
whether or not an intermolecular interaction between RGD peptides 
has occurred. The treatment group included two conditions for 
comparing effect of intermolecular conjugation. One was treated 14
and the other was sequentially treated 12 and 13. The results are 
shown in Figure 17, 18. 
In the control group, fluorescent signals of 12 or 13 in each FITC 
and TRITC channel located in the cells (Figure 17). In blocking 
group, each fluorescent signals of FITC and TRITC were observed on 
cells but there were no FRET signals. This suggest that FRET signals 
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can show intermolecular click reaction. In condition of sequentially 
treating 12 and 13, each fluorescent signals of FITC and TRITC were 
located inside the cells and they were co-localized. Moreover, the 
high intensity of FRET signals were observed in the merged site of 
FITC and TRITC inside of tumor cells (Figure 18). In contrast, 
although FITC and TRITC signals of 14 were observed inside the 
cells, the FRET signals shown low intensity. These results indicated 
that strategy of this study can induce internalization of RGD peptides 
via intermolecular conjugation, which occurred from FITC on 12 to 
TRITC on 13, and enhancement of tumor uptake.
Futhermore, RGD peptides conjugated with TCO and tetrazine for 
click reaction were analyzed by confocal microscopy imaging on 
U87-MG cells in following the above conditions, which were control, 
blocking and treatment group. The control group was treated with one 
of fluorescent conjugated RGD peptide (15 or 16). The pre-conjugated 
RGD peptide between 15 and ADIBO-NH2 (3-amino-1-(11,12-
didehydrodibenz[b,f]azocin-5(6H)-yl)-1-propanone) was treated as a 
blocking group. The treatment group included two conditions that 
were treated only 17 or sequentially addition of 15 and 16. The 
results are shown in Figure 19, 20. 
The results were similar with assay of RGD peptides, which 
conjugated with ADIBO and azide moiety. In the control group, 
fluorescent signals of 15 or 16 in each FITC and TRITC channel 
located in the cells (Figure 19). In blocking group, each fluorescent 
signals of FITC and TRITC were observed on cells but there were no 
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FRET signals. In condition of sequentially treating 15 and 16, each 
fluorescent signals of FITC and TRITC were located inside the cells 
and they were co-localized. Moreover, the higher FRET signals than 
treatment of 17 were observed in the merged site of FITC and 
TRITC inside of tumor cells (Figure 20). 
53
Figure 17. Images of confocal microscopy in control group on U87-MG cells. Condition; 
N3-K-FITC-D-[c(RGDyK)]-[c(RGDfK)] (12), ADIBO-D-TRITC-D-[c(RGDfK)]2 (13). 
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Figure 18. Images of FRET microscopy in U87-MG cells. Condition; 12 blocking with ADIOBO-NH2 and 13, only 
14, sequentially treatment of 12 and 13.
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Figure 19. Images of confocal microscopy in control group on U87-MG cells. Condition; 
Tz-K-FITC-D-[c(RGDyK)]-[c(RGDfK)] (15), TCO-K-TRITC-D-[c(RGDfK)]2 (16). 
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Figure 20. Images of FRET microscopy in U87-MG cells. Condition; 15 blocking with ADIOBO-NH2 and 16, only 
17, sequentially treatment of 15 and 16.
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In vitro internalization on U87-MG cells
The in vitro internalization study performed on U87-MG cells by 
using [123I]10 and various amounts of 4 (Figure 21). In the results, 
new method, which was sequentially treated non-labeled RGD 
peptides, has higher internalized RGD peptides than only [123I]10 on 
cancer cell. This results indicated that new strategy may enhance  
internalization of ligand.
Figure 21. Internalization of RGD peptides in U87-MG cells. (A) %Added 
dose of [123I]10 and internalized [123I]10 with 4 (B) ratio for internalization 
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5. Ex/In vivo experimental results
Ex vivo biodistribution in tumor xenograft
In ex vivo biodistribution studies, [123I]10 (dimer form) or [123I]11 
(tetramer form) were administered intravenously in U87-MG 
tumor-bearing nude mice model at four time points (Figure 22, 23). 
Both [123I]10 and [123I]11 were rapidly cleared from blood. The 
blood levels of two peptides were 0.79% ID/g and 1.77% ID/g at 60 
min post-injection, respectively. Rapid and high tumor uptakes of 
[123I]10 and [123I]11 were 14.1 ± 1.59% ID/g and 15.9 ± 1.6% ID/g 
at 30 min post-injection, respectively. Although in vitro binding 
affinities for integrin αvβ3 were slightly higher in [
123I]11 than in 
[123I]10, there was no significant difference in tumor uptakes between 
[123I]10 and [123I]11. The tumor uptakes of both RGD peptides 
decreased to lower than 8.9% ID/g at 2h post-injection. 
The [123I]10 and [123I]11 have similar clearance kinetics, which 
passed through renal excretion. The initial renal radioactivity of 
[123I]11 (24.2 ± 0.39% ID/g) was two times higher than that of the 
[123I]10 (11.6 ± 2.8% ID/g) at 30 min post-injection. Increasing 
arginine residues, which contains positive charge, may leads to high 
renal uptakes so that multimeric RGD peptides have major 
accumulation of radio activities on the renal pathway. Nevertheless, 
kidney uptakes of both RGD　peptides dramatically fell to 8.5 ± 0.6% 
ID/g and 4.6 ± 0.7% ID/g at 2 h post-injection, respectively. 
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The accumulation on normal brain was not observed because of 
low integrin αvβ3 expression and an intact blood-brain barrier (BBB).
The thyroid uptakes, which caused by the decomposition of RGD 
peptide to free 123I, was not observed on results of [123I]10 for 2 h 
(0.50 ± 0.09% ID/g). In contrast, thyroid uptakes unexpectedly 
increased at 2 h post-injection with [123I]11 (3.23 ± 0.59% ID/g). 
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Figure 22. Ex vivo biodistribution of [123I]10. Results were expressed as %ID/g; mean ± S.D. (n = 4, each time 
point). [123I]10 (0.74 MBq) was injected into U87-MG tumor bearing mice via tail vein.
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Figure 23. Ex vivo biodistribution of [123I]11. Results were expressed as %ID/g; mean ± S.D. (n = 4, each time 
point). [123I]11 (0.74 MBq) was injected into U87-MG tumor bearing mice via tail vein. 
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Small animal SPECT/CT imaging results
[123I]10 and [123I]11
  The SPECT/CT imaging of [123I]10 or [123I]11 in U87-MG bearing 
nude mice (n = 4, each time point) were performed for 90 min. 
Quantification of activity accumulation in tumor, kidney, liver and 
heart was observed (Figure 24).   
  The U87-MG tumor uptake of [123I]10 and [123I]11 was similar at 5 
min post-injection, which was 13.5 ± 1.3 % ID/g, 13.3 ± 4.1 % 
ID/g, respectively. The activity accumulation was reached the highest 
at 5 min post-injection and decreased to almost half in 90 min. 
Futhermore, similar kinetic and uptakes in liver and heart was 
observed on both the RGD peptides ([123I]10 or [123I]11). 
   The SPECT/CT images of both RGD peptides correlated with ex 
vivo biodistribution data. Positive correlation between ex vivo tumor 
radioactivity measurements and animal SPECT/CT image analysis 
(R2=0.889) was obtained (Figure 25). Thus, it appeared that 
ROI-derived %ID/g values and provide high-confidence values for 
assessing the angiogenic response in tumor-bearing mice.
  Thus, by co-relation with in vivo SPECT/CT images and ex vivo 
biodistribution data, effect of in vivo intermolecular conjugation (duet 
bioorthogonal clasp) was determined by in vivo SPECT/CT imaging.
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Figure 24. Comparison of small animal SPECT data for [123I]10 and [123I]11
Radioactivity of region of interest (ROI) for organs were determined as  
percentage injected dose per gram (%ID/g). Results are given as the means 
± S.D. (n = 4).
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Figure 25. Comparisons of tumor uptake of [123I]10 and [123I]11 analyzed 
by SPECT imaging and dissected biodistribution. Measurement of [123I]10, 
[123I]11 uptake and calculated tumor activity by in vivo animal SPECT 
analysis was compared to the true values, as measured ex vivo tumor 
uptake by gamma counter.
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In vivo intermolecular conjugation
  The SPECT/CT scans in U87-MG tumor-bearing mouse model were 
performed to evaluate the effects of in vivo intermolecular 
conjugation, which named Duet Bioorthogonal Clasp (DBC), with 
[123I]10 and 4 (ADIBO-D-[c(RGDfK)]2) for 2 h. Because this strategy 
included two RGD peptides, which were radioisotope labeled ([123I]10) 
and non-labeled (4) RGD peptiedes for sequential injection, two 
conditions were considered for determining the best condition of this 
new method (DCB). One was order of ligand injection and the other 
was amounts of non-labeled ligands. 
  First, [123I]10 was injected via the tail vein into the mouse and 
then three different amounts of 4 was subsequently added after 15 
min. Based on a reported pre-targeting study, amounts of non-labeled 
RGD peptides were selected (18 mg/kg, 1.8 mg/kg, and 0.18 mg/kg) 
[59]. 
  The initial tumor uptakes for 18 mg/kg, 1.8 mg/kg, and 0.18 mg/kg 
of 4 (12.4 ± 0.8% ID/g, 11.9 ± 0.9% ID/g, 12.6 ± 0.6% ID/g at 5 
min post-injection, respectively) were similar. However, the 
accumulation of radioactivity at 2 h post-injection. was significantly 
different (7.47 ± 2.45% ID/g, 7.41 ± 1.92% ID/g, and 9.52 ± 2.1% 
ID/g, respectively, Figure 26). These results suggested that new 
strategy with the lowest amount (0.18 mg/kg) of peptide 4 t could 
affect retention time of the RGD peptides at the tumor site for 2 h.
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Figure 26. Small animal SPECT/CT images-based measured tumor uptakes. 
Sequentially injection of [123I]10 and 4 (18 mg/kg, 1.8 mg/kg, 0.18 mg/kg) 
for 2 h in U87-MG bearing mouse model. Results are given as the means 
± S.D. (n = 3). (A) Protocol of small animal SPECT/CT imaging analysis 
(B) Comparison of tumor uptakes in different amounts of non-labeled ligand,  
[123I]10 and [123I]11.
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  Second, SPECT/CT scans were performed by changing the order of 
injection, in which non-labeled RGD peptide (18 mg/kg, 1.8 mg/kg, 
and 0.18 mg/kg) was added first, followed by the injection of [123I]10. 
  The results of SPECT/CT imaging in the tumors were shown in 
Figure 27. Tumor uptakes of different conditions (18 mg/kg, 1.8 
mg/kg, and 0.18 mg/kg) have no significant difference between at 15 
min (9.30 ± 1.96% ID/g, 9.03 ± 1.72% ID/g, and 9.19 ± 1.31% 
ID/g, respectively) and at 2 h post injection. (8.45 ± 4.59% ID/g, 
8.53 ± 1.99% ID/g, and 6.44 ± 1.30% ID/g).
  However, the absolute initial tumor uptake value was lower than 
that of earlier condition, when the radiolabeled RGD peptide was 
injected before the non-labeled RGD peptide. This result suggests that 
the excess non-labeled RGD peptide may act inhibitor to interrupt the 
binding of radiolabeled RGD peptide to integrin αvβ3. In addition, 
AUC (area under curves) value, which is associated with effect of 
therapy, was lower than earlier condition.
  Thus, from the in vivo imaging studies the best condition for this 
strategy was determined. The radiolabeled RGD peptide ([123I]10) was 
injected and then subsequently the lowest amount of non-labeled RGD 
peptide (4) for inducing in vivo intermolecular conjugation to prolong 
retention time of ligand on cancer cells. 
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Figure 27. Small animal SPECT/CT images-based measured tumor uptakes. 
Sequentially injection of 4 (18 mg/kg, 1.8 mg/kg, and 0.18 mg/kg) and 
[123I]10 dimer for 120 min in U87-MG xenograft model. Results are given 
as the means ± S.D. (n = 3). (A) Protocol of small animal SPECT/CT 
imaging analysis (B) Comparison of tumor uptakes in different amounts of 
non-labeled ligand, [123I]10 and [123I]11.
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  To identify the effect of in vivo intermolecular conjugation, the 
tumor uptakes were compared according to the type of RGD ligand 
([123I]10; dimer form, [123I]11; tetramer form) and the best condition 
of duet bioorthogonal clasp (sequentially injection of [123I]10; dimer 
form and 4; dimer form) (Figure 28). 
  The initial tumor uptakes of [123I]10, [123I]11, and [123I]10 + 4 were 
13.5 ± 1.3% ID/g, 13.3 ± 4.1% ID/g, and 12.6 ± 0.6 % ID/g at 5 
min post-injection, respectively. After 85 min of administration, the 
tumor uptakes of [123I]10, [123I]11 and [123I]10 + 4 were 5.2 ± 2.1% 
ID/g, 5.4 ± 1.8 % ID/g, and 10.2 ± 1.7 % ID/g, respectively. In the 
case of [123I]10, [123I]11, tumor uptakes significantly decreased for 85 
min and remained only 39% and 41% of total radioactivities. 
However, in vivo intermolecular conjugation (DBC, [123I]10 + 4) 
showed no significant difference in tumor uptakes and remained at
over 81% of total radioactivities for 85 min. In addition, half-life of 
new strategy was 2.5 times higher than that of [123I]10 and [123I]11.
  These results suggest that in vivo intermolecular conjugation 
affected the residence time of RGD peptides indicating stronger and 
more prolonged binding with integrin αvβ3 owing to in vivo click 
reaction, which conjugated between [123I]10 and 4. In addition, these 
results may be explained by the results of in vitro confocal imaging, 
which showed that the intermolecular conjugation would induce the 
internalization into tumor cells. Therefore, this new strategy could lead 
to improvement in the retention time of RGD peptides and achieve 
enhanced internalization of multimeric RGD peptides into tumor cells 
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by forming cluster of ligand bound integrins. 
Figure 28. Comparisons of tumor uptake of [123I]10 and [123I]11 and 
[123I]10 + 4 (DBC). Small animal SPECT/CT images-based measured tumor 
uptakes for 85 min post-injection in U87-MG tumor bearing mice. (n = 3 
or 4 for each group). Results are expressed as %ID/g.
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  As the in vivo intermolecular conjugation induced prolong retention 
time of RGD peptide, SPECT/CT scans were performed in the 
U87-MG tumor-bearing mouse model for 24 h. The results are shown 
in Figure 29. The tumor uptake maintained approximately 60% 
(decay-corrected) for 24 h compared with initial tumor uptake.
Figure 29. Small animal SPECT/CT images-based measured tumor uptakes 
by DBC for 24 h. Uptake (decay-corrected) of tumor for 24 h in U87-MG 
xenografted model (n = 3).
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DISCUSSION
  The feasibility of in vivo intermolecular conjugation (Duet 
Bioorthogonal Clasp, DBC) with RGD peptides for angiogenesis 
targeted therapy was evaluated in the SPECT imaging studies by 
using U87-MG tumor bearing mouse model.
   This study describs the synthesis and radiosynthesis of different 
RGD peptide dimers which are available in vivo intermolecular 
conjugation using Click reaction. In addition, different RGD peptide 
dimers, which contain pairs for Click reaction, are easily modified as 
fluorescent imaing probe as well as SPECT radiotracer. The prepared 
RGD peptides, [123I]10 (dimer form) and [123I]11 (tetramer form), had 
a high binding affinity for integrin αvβ3 as determined by competitive 
cell-binding assay. Then, the in vivo binding affinity and specificity 
of [123I]10 and [123I]11 was also confirmed by ex vivo biodistribution 
studies and small animal SPECT/CT scans.
  Although radiolabeled RGD peptides has been developed for tumor 
therapy, RGD-based tracers washed out rapidly from the tumor site 
because of possibly inadequate binding with integrin αvβ3 under in 
vivo environment. This challenge has limited the application of  
targeted cancer therapy. 
  DBC, which induced intermolecular conjugation by an sequential 
injection of RGD peptides, was investigated by using FRET analysis 
and SPECT/CT imaging for strong binding between integrin αvβ3. The 
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results of in vitro FRET　analysis indicated that this strategy has the 
potential for inducing internalization into the cancer cell. Fluorescence 
signals by intermolecular conjugation were localized in inside U87-MG 
cells.
  For measuring tumor uptake, in vivo SPECT/CT imaging studies on  
different amounts of non-labeled RGD peptide and the change of 
injection order were carried out to optimize condition for in vivo
intermolecular conjugation was established. Moreover, non-radiolabeled 
RGD peptide may act as a blocker that interrupted the binding of 
radiolabeled RGD peptide to integrin αvβ3. The usage of the lowest 
amounts of non-labeled RGD peptide and later injection could prolong 
the retention time of ligand on the tumor.
  In the comparison of tumor uptake between [123I]11 (tetramer form) 
and DBC, the RGD peptides remained at target site for longer  for 2 
h by new strategy. This result suggests that tetramer form, prepared 
by in vitro click reaction, was not enough for simultaneous binding to 
adjacent four integrin αvβ3. In the contrast, this strategy may lead to 
binding of all RGD peptide for integrin αvβ3 via intermolecular 
conjugation and to induce internalization into tumor cells by clustering 
of integrins via strong conjugation of ligands.
  These results suggest that this method can pave the way to various 
successful application such as targeted radionuclide therapy, therapeutic 




  In this study, a new in vivo intermolecular conjugation-based 
strategy was demonstrated to induce internalization of RGD peptides 
into cancer cells more efficiently. 
  The RGD peptides for in vivo intermolecular conjugation were 
successfully synthesized and labeled with fluorescent dyes or 
radioisotopes. In vitro FRET analysis using confocal microscopy  
suggested that new method induced internalization of RGD peptides 
into the cancer cells. The results of in vivo and ex vivo studies with 
iodine-123 labeled RGD peptides indicated that tumor uptake was  
maintained for 24 h by new method. 
  Thus, this new strategy could be used as a promising tool not only 
for anti-angiogenic radiotherapy, but also for enhancing drug delivery, 
in general.
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[APPENDIX 1] Radioiodo-labeled RGD peptides
Iodine is an ideal radioisotope for nuclear medicine diagnostics and 
therapy. 131I is suitable for therapeutic radionuclide, which has short 
range beta radiation (971 keV) and also emitted gamma ray, has 
adequate the half-life time (8.06 days) for therapeutic treatments [1]. 
In addition, iodination of biomolecules is well established. 
  123I is usually produced by cyclotron from bombardment of 
antimony-121 or tellurium-122 or –124 and has been used for 
diagnostics due to emit only gamma ray [2]. The half-life time (13.2 
h) sufficiently long to measure biokinetics for diagnosis. In addition, 
131I is used for radionuclide therapy as converting 123I to 131I without 
modifying precursors [3]. For these properties, 123I and 131I are 
“matched pairs” for theranostics, which is useful radioisotopes for in 
vivo imaging and therapy, respectively.
References [1] Mandel S.J., Shankar L.K., Benard F., Yamamoto A., Alavi 
A. Superiority of Iodine-123 Compared with Iodine-131 scanning for thyroid 
remnants in patients with differentiated thyroid cancer. Clin Nucl Med.
2001;26:6. [2] Buscombe J.R. Radionuclides in the management of thyroid 
cancer. Cancer Imaging. 2007;7:202.[3] Yordanova A., Eppard E., Kürpig S., 
Bundschuh R.A., Schönberger., Gonzalez-Carmona M., Feldmann G., 
Ahmadzadehfar H., Essler M. Theranostics in nuclear medicine practice. 
Onco Targets Ther. 2017;10:4821.
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[APPENDIX 2] FRET　microscopy　　
  Fluorescence resonance energy transfer (FRET) is a photophysical 
phenomenon, which relies on distance dependent transfer of energy 
between donor and acceptor fluorophores [1]. Conformational dynamic 
and interactions of biomolecules is observed in real time by 
measuring FRET signals [2]. Donor fluorophore is excited by external 
light and energy of excited state transferred to acceptor fluorophore 
[3]. This leads to reduce donor’s fluorescence intensity and to 
increase acceptor’s emission intensity. Fluorescence signals by 
transference of energies depend on distances between donor and 
acceptor. This technique is useful to evaluate changes in nanometer 
scale distances.　Several pairs of fluorescence dyes, which have large 
spectral separation between donor and acceptor emissions, are used for 
FRET [4]. Among small organic dyes, fluorescein isothiocyanate 
(FITC) and tetramethylrhodamin (TRITC) are also suitable pairs for 
FRET analysis. Two fluorescence dyes have proper spectrums for 
transferring energies from donor to acceptor [5]. The selected dyes 
show absorption and emission spectra overlap for transferring energies 
from emission of the donor to excitation of the acceptor. In this 
study, we selected pairs (FITC and TRITC) of small organic dyes to 
evaluate conjugation between RGD dimers by click reaction. 
   
77
Diagram of fluorescence resonance energy transfer (FRET) [3].
FITC TRITC
Ex. Ex.Em. Em.
Excitation (Ex.) and emission (Em.) spectra of FITC and TRITC. The FITC 
emission spectrum overlaps the TRITC excitation spectrum for FRET
References [1] Selvin P.R. The renaissance of fluorescence resonance energy 
transfer. Nat Struct Biol. 2000;7:730. [2] Yamauchi F., Kamioka Y., Yano 
T., Matsuda M. In vivo FRET imaging of tumor endothelial cells highlights 
a role of low PKA activity in vascular hyperpermeability. Cancer Res. 
2016;76:5266. [3] Van der Wal S., de Korne C.M., Sand L.G.L. 
Bioorthogonally Applicable Fluorescence Deactivation Strategy for Receptor 
Kinetics Study and Theranostic Pretargeting Approaches. ChemBioChem. 
2018;19:1758. [4] 1. Lleress D., Swift S., Lamond A.I. Detecting 
Protein-Protein Interactions In Vivo with FRET using Multiphoton 
Fluorescence Lifetime Imaging Microscopy (FLIM). Curr Protoc Cytom.
2007:1. [5] Fehr M., Lalonde S., Lager I., Wolff M.W., Frommer WB. In 
vivo imaging of the dynamics of glucose uptake in the cytosol of COS-7 
cells by fluorescent nanosensors. J Biol Chem. 2003;278:19127.
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국 문 초 록
종양 표적 치료는 기존의 항암제, 수술적 접근 또는 외부 방사
선조사를 이용한 방법과는 달리 종양의 특이적 활성에 관여하는 
바이오마커만을 표적으로 하는 치료 방법이다. 현재까지 알려진 
종양 표적 치료 방법으로는 표적항암제 치료, 방사성동위원소 치
료, 광역학 치료 같은 방법이 있으며 모두 종양세포의 사멸과 함
께 정상 세포의 손상을 최소화하는 목적을 지니고 있다. 이 치료
에 사용되는 약물이나 펩티드 또는 단백질은 종양 특이 바이오마
커에 높은 결합능과 정상 장기에는 낮은 분포 그리고 종양에 높은 
머무름을 가져야 하며, 종양세포 내로 세포 내재화(internalization)
가 요구된다.
본 연구에서는 종양에 발현되는 하나의 특이적 수용체를 표적
하는 서로 다른 펩티드를 순차적으로 주입 후, 수용체에 결합된 
펩티드들 간에 체내 분자 간 결합 반응을 유도하는 방법(Duet
Bioorthogonal Clasp)을 고안하였다. 이 방법은 종양 주변에 분포
하는 수용체에 자리 잡은 펩티드 간의 체내 분자 간 결합으로 수
용체들 사이에 복합결합체(cluster)를 형성시키고 기존의 표적 수용
체와 펩티드 혼합체가 종양 세포 내부로 이동되는 현상
87
(endocytosis)을 유도하여 주입한 펩티드의 종양세포 내 머무름을 
증진시켜 표적 치료 효과를 향상시키는 목적이 있다. 이를 위해 
종양 특이 바이오마커로 종양 신생혈관생성에 연관되어있고 종양 
근처 혈관에 존재하는 인테그린 αvβ3 수용체를 선택하였고 이에 
높은 결합력을 갖는 RGD 펩티드들을 리간드로 합성하였다. 서로 
다른 두 펩티드의 체외 종양 세포에서 이동 및 분포를 확인하고자 
형광영상이 가능한 형광 염료 (FITC 또는 TRITC)가 도입된 RGD
펩티드를 합성하였으며, 체내 종양에서 분포를 확인하고자 단일광
전자단층촬영(SPECT) 영상 획득을 위해 펩티드 잔기의 타이로신
에 방사성동위원소(123I 또는 125I)를 표지하였다.
새로 고안한 방법인 두 개의 서로 다른 RGD 펩티드로 체내 분
자 간 결합을 유도 하였을 때, 종양 세포 내로 이동하는 정도가 
현격히 증가됨을 FRET 형광 영상분석을 통해 확인하였다. 방사성
요오드가 도입된 RGD 펩티드를 이용한 체내 SPECT/CT 영상에서
도 하나의 RGD 펩티드는 2시간 후 종양에 39%가 남아있는 것에 
비해, 본 연구의 방법은 81%로 종양 섭취가 남아 있음을 확인하였
으며 24 시간 동안에도 60%의 종양 섭취가 유지되고 있음을 확인
하였다.
본 연구에서 종양 표적 치료를 위해 고안된 방법은 종양 근처의 
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수용체 간 복합결합체를 형성을 도와 리간드의 종양 세포 내재화 
촉진을 유도하는 방법임을 확인하였으며 향후에 종양의 방사성동
위원소치료 및 항암약물 전달 방법과 같은 다양한 종양표적치료에 
이용이 확대될 것으로 기대한다.
주요어 : 표적 종양 치료, 세포 내 이입, 신생혈관, RGD 펩타이드,
복합결합체
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